Trial Information
Inclusion Criteria:
- Subjects must have histologically proven breast cancer
- Subjects are being considered for preoperative chemotherapy
- Subjects must be ≥ 18 years old.
Exclusion Criteria:
- Children will be excluded from this study.
- Pregnant women and women who are breast feeding will be excluded from this study.
(The "PET Procedure Screening Form" will be used to identify and exclude subjects who
are pregnant or breastfeeding. A urine pregnancy test/or serum beta HCG will also be
performed for women of child bearing potential)
- Patients who are acutely ill who are deemed by their treating physician as not
suitable candidates for this study
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Changes in the standard uptake value (SUV) and Gadolinium contrast parameters will be used as a predictor of response then correlated to complete pathologic response measured at the time of definitive surgery.
Outcome Time Frame:
Prior to chemotherapy, within 7-14 days following the start of chemotherapy and immediately prior to surgery.
Safety Issue:
No
Principal Investigator
A. Bapsi Chakravarthy, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
VICC BRE 09108
NCT ID:
NCT01222416
Start Date:
October 2010
Completion Date:
December 2019
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
Vanderbilt-Ingram Cancer Center |
Nashville, Tennessee 37232-6838 |